[The colibacillosis of the pig (author's transl)].
A review of recent knowledges of the specific determinants of Escherichia coli pathogenicity allows the development of new effective immunisation against the colibacillosis of the pig. Especially experimental and field trials provide promising results by oral or parenteral vaccinations, with attenuated bacteria neutralising the effect of enterotoxins or with partially purified protein surface antigen preventing bacterial attachment to the intestinal wall. However it is necessary to bear in mind the necessity of not neglecting sanitary management.
D000284:Administration, Oral; D000818:Animals; D000831:Animals, Newborn; D000942:Antigens, Bacterial / Q000032:analysis; D001428:Bacterial Vaccines / Q000008:administration & dosage; D003126:Colostrum / Q000276:immunology; D004731:Endotoxins / Q000633:toxicity; D004768:Enterotoxins / Q000633:toxicity; D004926:Escherichia coli / Q000276:immunology / Q000472:pathogenicity; D004927:Escherichia coli Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D005260:Female; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D007279:Injections, Subcutaneous; D008297:Male; D012499:Sanitation; D013552:Swine; D013553:Swine Diseases / Q000276:immunology / Q000517:prevention & control; D014611:Vaccination / Q000662:veterinary
D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D004731:Endotoxins; D004768:Enterotoxins; D007071:Immunoglobulin A, Secretory
Colibacillose du porc